Sarepta (SRPT) CFO has 256 shares withheld to cover RSU taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Sarepta Therapeutics, Inc. Chief Financial Officer Ryan Ho-Yan Wong reported a small share disposition tied to tax withholding, not an open-market trade. On March 11, 256 shares of common stock were withheld by the company at $17.03 per share to cover taxes on restricted stock units that vested from a grant dated March 10, 2025.
After this tax-withholding event, Wong directly holds 135,064 shares of Sarepta common stock. Because the shares were withheld to satisfy tax obligations rather than sold in the market, this filing reflects a routine compensation-related adjustment rather than a discretionary purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Wong Ryan Ho-Yan
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 256 | $17.03 | $4K |
Holdings After Transaction:
Common Stock — 135,064 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Sarepta Therapeutics (SRPT) report for its CFO?
Sarepta’s CFO, Ryan Ho-Yan Wong, reported a routine tax-withholding transaction. The company withheld 256 common shares to cover taxes due on vested restricted stock units from a March 10, 2025 grant.
Was the Sarepta (SRPT) CFO’s Form 4 transaction an open-market sale?
No, the Form 4 transaction was not an open-market sale. The 256 shares were withheld by Sarepta to satisfy tax obligations from restricted stock unit vesting, a standard compensation-related adjustment rather than a discretionary share sale.